Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61K-047/00
A61K-038/16
출원번호
US-0157977
(2011-06-10)
등록번호
US-8383580
(2013-02-26)
발명자
/ 주소
Rui, Liangyou
Zhou, Yingjiang
출원인 / 주소
The Regents of the University of Michigan
인용정보
피인용 횟수 :
0인용 특허 :
4
초록
A method of treating an LCN13-related condition is provided comprising administering to a patient in need thereof a therapeutically effective amount of a lipocalin or a physiologically active fragment thereof.
대표청구항▼
1. A method of treating a lipocalin (LCN)13-related condition comprising administering to a patient in need thereof a therapeutically effective amount of a lipocalin selected from the group consisting of LCN13, LCN1, LCN3, LCN4, LCN14, odorant binding protein (OBP)2B, OBP2A, and a fragment of LCN13
1. A method of treating a lipocalin (LCN)13-related condition comprising administering to a patient in need thereof a therapeutically effective amount of a lipocalin selected from the group consisting of LCN13, LCN1, LCN3, LCN4, LCN14, odorant binding protein (OBP)2B, OBP2A, and a fragment of LCN13 comprising residues 54 through 124 in SEQ ID NO: 1, wherein the LCN-13 related condition is a metabolic disorder or a cardiovascular disease. 2. The method of claim 1 wherein said lipocalin is at least 95% identical to SEQ ID NO: 1. 3. The method of claim 1 wherein said lipocalin comprises the amino acid sequence set out in SEQ ID NO: 1. 4. The method of claim 1 wherein said metabolic disorder is selected from the group consisting of type 1 diabetes, type 2 diabetes, hyperglycemia, hyperinsulinemia, insulin resistance, and obesity. 5. The method of claim 4 wherein said lipocalin is co-administered with a therapeutically effective amount of insulin. 6. The method of claim 1 wherein the cardiovascular disease is selected from the group consisting of hypercholesterolemia, non-familial hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemia, atherosclerosis, coronary heart disease, early onset coronary heart disease, dyslipidemia, hypertriglyceridemia, hyperlipidemia, and hyperfattyacidemia. 7. The method of claim 1, wherein the LCN-13 related condition is a cardiovascular disease selected from the group consisting of hepatic steatosis, non-alcoholic steatohepatitis, cirrhosis, liver failure, and non-alcoholic fatty liver disease.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (4)
Tom Henry K. (La Honda CA) Rowley Gerald L. (Cupertino CA), Concentrating zone method in heterogeneous immunoassays.
de Jaeger Nikolaas C. J. (Hove BEX) Monbaliu Marcel J. (Mortsel BEX) Noppe Marcus J. M. (Kalmthout BEX) Konings Frank J. (Antwerpen BEX), Immunoassay using colorable latex particles.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.